AMSbiopharma presented today, in an online event, the results of its Innovation Plan, developed over the past 18 months with the support of the Galician Innovation Agency (GAIN) through the Innova Pyme 2024 program. This initiative strengthens the company’s competitive position in the global biopharmaceutical sector by leveraging intangible innovation, implementing new quality protocols, promoting intrapreneurship, and expanding internationally.
To ensure the success of the plan, the company also reinforced its team by incorporating highly qualified professionals, recruited under strict standards of technical and professional excellence.
Intangible innovation and new collaborative projects
Throughout the implementation of the plan, AMSbiopharma has launched research projects and established agreements with public and private entities that have helped diversify its activities, enhance staff know-how, and open up new lines of work. These collaborations have strengthened the company’s competitiveness and generated key technical knowledge to meet the challenges of a constantly evolving sector.
Continuous improvement in quality and technology
The company is driving the continuous improvement of its quality protocols to ensure the highest standards of safety, efficacy, and reliability in its analytical processes. In addition, technological innovations in data encryption and control have been incorporated, improving the traceability and transparency of processes. These advances are further reinforced by the opening of new facilities, designed to expand AMSbiopharma’s capacity to deliver high-value analytical services.
A culture of intrapreneurship
The Innovation Plan has also strengthened the company’s entrepreneurial culture. Leveraging synergies with the different companies of the AMSlab Group, knowledge-sharing has been fostered and initiatives promoted in which employees themselves have played an active role in developing innovative projects.
International presence and mission to the United States
Internationalization has been another cornerstone of the plan. AMSbiopharma has rolled out market prospecting strategies in new countries, with milestones such as a trade mission to North Carolina. This trip enabled the company to establish strategic partnerships with research centers and open new avenues of cooperation aimed at positioning Galicia as a key player in the international biotechnology sector.
Commitment to Galician biotechnology
With the completion of this plan, AMSbiopharma consolidates its commitment to technological innovation and continuous process improvement, reaffirming its role as a driver of the biotechnology sector in Lugo and Galicia.
“This project marks a step forward for AMSbiopharma on its path towards differentiation, internationalization, and innovation. With this commitment, we are enhancing our competitiveness by delivering high-value services to the biopharmaceutical sector,” said the company’s management.
AMSbiopharma’s Innovation Plan was co-funded by the Galician Innovation Agency (GAIN) through the Innova Pyme 2024 business support program.
